Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMBR | P28336 | 15/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6182113 | 0.88 | NMBR (0.50) | NMBR | |
| SCHEMBL6254953 | 0.88 | NMBR (0.49) | NMBR | |
| SCHEMBL6185509 | 0.85 | NMBR (0.72) | NMBR | |
| SCHEMBL6182008 | 0.85 | NMBR (0.47) | NMBR | |
| SCHEMBL7107440 | 0.83 | NMBR (0.46) | NMBR | |
| SCHEMBL6179841 | 0.77 | NMBR (0.74) | NMBR | |
| SCHEMBL6184335 | 0.74 | NMBR (0.64) | NMBR | |
| SCHEMBL6180744 | 0.74 | NMBR (0.48) | NMBR | |
| SCHEMBL6252536 | 0.72 | NMBR (0.66) | NMBR | |
| SCHEMBL6253230 | 0.71 | NMBR (0.43) | NMBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0920424-B1 | NON-PEPTIDE BOMBESIN RECEPTOR ANTAGONISTS | WARNER LAMBERT CO (US) | 2005-11-30 | — | — | EP | claimed |
| EP-1333824-B1 | TREATMENT OF SEXUAL DYSFUNCTION WITH BOMBESIN RECEPTOR ANTAGONISTS | WARNER LAMBERT CO (US) | 2005-09-07 | — | — | EP | claimed |
| US-20040087561-A1 | Treatment of sexual dysfunction | WARNER-LAMBERT COMPANY LLC | 2004-05-06 | — | — | US | claimed |
| EP-1333824-A2 | TREATMENT OF SEXUAL DYSFUNCTION | Warner-Lambert Company LLC (US) | 2003-08-13 | — | — | EP | claimed |
| US-20020169101-A1 | Treatment of sexual dysfunction | WARNER-LAMBERT COMPANY | 2002-11-14 | — | — | US | claimed |
| WO-2002040008-A2 | TREATMENT OF SEXUAL DYSFUNCTION WITH NON PEPTIDE BOMBESIN RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY LLC (US) | 2002-05-23 | — | — | WO | claimed |
| US-6194437-B1 | ANTIDEPRESSANTS; ANTICANCER AGENTS; GASTROINTESTINAL DISORDERS; COGNITION ACTIVATORS | WARNER-LAMBERT COMPANY | 2001-02-27 | — | — | US | claimed |
| EP-0920424-A1 | NON-PEPTIDE BOMBESIN RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1999-06-09 | — | — | EP | claimed |
| WO-1998007718-A1 | NON-PEPTIDE BOMBESIN RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1998-02-26 | — | — | WO | claimed |
| EP-0920424-B1 | NON-PEPTIDE BOMBESIN RECEPTOR ANTAGONISTS | WARNER LAMBERT CO (US) | 2005-11-30 | — | — | EP | disclosed |
| EP-1333824-B1 | TREATMENT OF SEXUAL DYSFUNCTION WITH BOMBESIN RECEPTOR ANTAGONISTS | WARNER LAMBERT CO (US) | 2005-09-07 | — | — | EP | disclosed |
| US-20040087561-A1 | Treatment of sexual dysfunction | WARNER-LAMBERT COMPANY LLC | 2004-05-06 | — | — | US | disclosed |
| EP-1343498-A1 | NOVEL USES OF NON-PEPTIDE BOMBESIN RECEPTOR ANTAGONISTS FOR TREATING ANXIETY AND PANIC DISORDERS | Warner-Lambert Company LLC (US) | 2003-09-17 | — | — | EP | disclosed |
| EP-1333824-A2 | TREATMENT OF SEXUAL DYSFUNCTION | Warner-Lambert Company LLC (US) | 2003-08-13 | — | — | EP | disclosed |
| US-20020169101-A1 | Treatment of sexual dysfunction | WARNER-LAMBERT COMPANY | 2002-11-14 | — | — | US | disclosed |
| WO-2002049644-A1 | NOVEL USES OF NON-PEPTIDE BOMBESIN RECEPTOR ANTAGONISTS FOR TREATING ANXIETY AND PANIC DISORDERS | WARNER-LAMBERT COMPANY LLC (US) | 2002-06-27 | — | — | WO | disclosed |
| WO-2002040008-A2 | TREATMENT OF SEXUAL DYSFUNCTION WITH NON PEPTIDE BOMBESIN RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY LLC (US) | 2002-05-23 | — | — | WO | disclosed |
| US-20020058606-A1 | Treatment of sexual dysfunction | WARNER-LAMBERT COMPANY | 2002-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058606-A1 | Treatment of sexual dysfunction | BRS3, GNRHR, VIPR2 | NMBR 122/4885 |
| US-20040087561-A1 | Treatment of sexual dysfunction | BRS3, MME, ECE1 | NMBR 258/4885 |
| US-20020169101-A1 | Treatment of sexual dysfunction | BRS3, MME, ECE1 | NMBR 258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.